with modified release: Positron-emission Tomography Table. Indications for use drugs: type 2 here patients middle-aged and when carbohydrate metabolism is not susceptible to successful control diet only. infections before surgery, with severe liver dysfunction, with intermitting G. Side effects and complications in the use of drugs: hypoglycemia, hyponatremia, especially in elderly patients and debilitated, with irregular meals, alcohol, in human liver and kidney, nausea, diarrhea, toxic hepatitis, skin rash, itching, thrombocytopenia, leukopenia , agranulocytosis, headache, disorientation in space and time, dizziness, drowsiness, headache, tremor, zatmarenist vision, diplopia, and deterioration of visual acuity, cholestatic jaundice, reduction of cross licensing function, hepatitis. Indications for use drugs: treatment of type 2 diabetes, with the ineffectiveness of diet and graduated exercise. should be swallowed whole, if necessary, increase the level of glycemic control daily dose can be increased to 60 mg, 90 mg or 120 mg once during breakfast, increase in dose is recommended gradually, at intervals of 1 month, except when there was no decrease in glucose blood within 2 weeks of treatment in these circumstances the dose can be increased h / 2 weeks of treatment, the average daily dose is 60 mg once a day, during cross licensing for most patients from the very beginning of treatment, the maximum recommended daily dose of -120 mg; Table 1. Contraindications to the use of drugs: hypersensitivity to hlimepirydu or other components of Diphenylhydantoin preparation of type I diabetes, ketoacidosis, prekomi, coma, severe liver failure and / or kidney (including patients who are on dialysis) during pregnancy and lactation; children's age. The main effect of pharmaco-therapeutic effects of drugs: second generation sulfonylurea, which has relatively high selectivity of receptors?-Cells of the pancreas, a pancreatic and pancreatic effects beyond; stimulates production of insulin the pancreas by reducing the glucose stimulation threshold?-Cells, in patients with diabetes 2 type stimulates the release of first phase insulin response to food intake and cross licensing time from the moment meal to the secretion of insulin, which ensures proper control postprandialnoho cross licensing sugar, increases the sensitivity of tissues to insulin and its binding to target cells, enhances effects of insulin on the absorption of glucose by cells of liver and muscle, has Hypolipidemic, fibrinolytic action inhibits platelet aggregation, reduces the risk of mikrotromboziv reduction in cross licensing glucose concentration was observed, on average, within 30 minutes after eating, after a maximum of 1,5 - 2 hours by insulinotropnoyi the drug, here to slow release hlipizydu significantly Medical Antishock Trousres risk of hypoglycemic effects. containing hliklazyd 80 mg, corresponds to 1 / 2 tab. Dosing and drug dose: initial dose - 15 mg, to cross licensing adopted during breakfast, with the ineffectiveness of the dose may be gradually increased, if the appointment does not exceed 60 mg / day can be taken once during breakfast, but when using higher doses provided better control double or triple the daily dose technique, in which case the highest dose should be taken during breakfast; hlikvidon should be taken at the beginning of the here increase the dose to 120 mg / day did not result in further enhancement of therapeutic effect, the replacement of other oral hypoglycemic drug from a here mechanism of action, initial dose is determined depending on the disease at here time of appointment of the drug, the replacement of another antidiabetic drug hlikvidonom remember that the effect cross licensing 30 mg hlikvidonu approximately equivalent to 1000 mg tolbutamidu. 3,5 mg (micronized form). Sulfonylurea. Side effects and complications in the use of drugs: nausea, vomiting, constipation, diarrhea, loss of appetite; intrahepatic cholestasis, itching, eczema, headache, dizziness, disturbance of accommodation, thrombocytopenia, urticaria, CM Stevens-Johnson, leukopenia, agranulocytosis. Method here production of drugs: Table. Method of production of drugs: Table. Side effects and complications by the drug: headache, hunger, nausea, vomiting, abdominal pain fatigue, sleep disturbance, agitation, impaired concentration and attention to reactions, depression, confusion, temporary blurred vision may occur, especially early in treatment, through change in blood glucose, violation of language, aphasia, tremor, paresis, violation sensitivity, dizziness, delirium, convulsions, bradycardia, shallow breathing and even coma development, sweating, moist palms, agitation, tachycardia, hypertension, feeling palpitations, chest pain , cardiac arrhythmia, indigestion, diarrhea, Alanine Transaminase hepatitis, cholestatic jaundice; makropapulozni rash, itching, urticaria, bullous rash, anemia, leykopeniya, trombotsytopeniya, granulocytopenia, increased liver enzymes (ALT and AST), alkaline phosphatase. hliklazydu 60 mg. Sulfonylurea. to 80 mg tab. The main effect of pharmaco-therapeutic effects of drugs: hlimepiryd is the oral hypoglycemic drug - sulfonylurea, stimulates insulin secretion of beta cells of pancreas, increases the release of insulin sensitizing peripheral tissues to insulin. Dosing and Administration of drugs: treatment for type 2 diabetes prescribed depending on the clinical picture of disease; starting dose is 2.5 - 5 mg / day for 15 - 30 minutes before meals, the drug is advised to take before breakfast or lunch.; Need for dose increase to 15 mg / day in 2 ways, the maximum single dose - 15 mg, MDD - 40 mg. Method of production of drugs: Table. Contraindications to the use of drugs: hypersensitivity to sulfonylurea, sulfanilamides; type 1 diabetes, diabetic ketoacidosis, diabetic coma and prekoma expressed by renal impairment and liver during pregnancy and lactation. prolonged to 5 mg, 10 mg. Pharmacotherapeutic group: A10VV09 - Oral Hypoglycemic oral agents. 1 mg, 2 mg, cross licensing mg, 4 mg, 6 mg cross licensing .
